iLIVER最新文献

{"title":"Duodenal varices and evaluation of endoscopic cyanoacrylate injection for treatment of duodenal variceal bleeding","authors":"Jin-dong Chu ,&nbsp;Qian Bi ,&nbsp;Yan-ling Wang,&nbsp;Xue-mei Ma,&nbsp;Bo Liu,&nbsp;Liang Wu,&nbsp;Shuai Wang,&nbsp;Li-jun Shen,&nbsp;Xiao-bao Qi,&nbsp;Zheng Lu","doi":"10.1016/j.iliver.2025.100143","DOIUrl":"10.1016/j.iliver.2025.100143","url":null,"abstract":"<div><h3>Background and aims</h3><div>Duodenal varices (DVs) are a rare complication of portal hypertension. This study analyzed the clinical characteristics of DVs and examined the efficacy of endoscopic cyanoacrylate injection for duodenal variceal bleeding.</div></div><div><h3>Methods</h3><div>The clinical data of patients with DVs treated in our hospital from March 2013 to May 2024 were retrospectively analyzed.</div></div><div><h3>Results</h3><div>During the study period, 80,850 patients underwent gastroscopy for a total of 122,040 endoscopy sessions. DVs were diagnosed in 52 patients. Eight patients with DVs exhibited duodenal variceal bleeding (15.4%). The overall prevalence of DVs was 0.08%.The prevalence of DVs among patients with upper gastrointestinal varices was 0.16%. The most common etiology of DVs was liver cirrhosis (92.3%). DVs location was the descending segment of the duodenum in 34 patients (65.4%). Forty-four patients (84.6%) had concomitant esophageal and gastric varices. Successful hemostasis was achieved at the time of endoscopy in all patients undergoing emergency endoscopic treatment using cyanoacrylate injection. The 6-week mortality rate was 12.5%. The rebleeding rate was 12.5%.</div></div><div><h3>Conclusions</h3><div>DVs are uncommon, even in hospitals where liver disease is prevalent. Emergency endoscopic cyanoacrylate embolization appears to be highly effective. Complete vein embolization may be considered for patients in poor condition. Age &gt;65 years and low hemoglobin concentration are predictors of duodenal variceal bleeding.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100143"},"PeriodicalIF":0.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of metabolic signatures implicated in the progression from hepatitis to cirrhosis to hepatocellular carcinoma","authors":"Simiao Yu ,&nbsp;Sici Wang ,&nbsp;Jiahui Li ,&nbsp;Haocheng Zheng ,&nbsp;Ping Li ,&nbsp;Wenya Rong ,&nbsp;Jing Jing ,&nbsp;Tingting He ,&nbsp;Yongqiang Sun ,&nbsp;Liping Wang ,&nbsp;Zhenyu Zhu ,&nbsp;Xia Ding ,&nbsp;Ruilin Wang","doi":"10.1016/j.iliver.2024.100142","DOIUrl":"10.1016/j.iliver.2024.100142","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. The mechanisms driving the transition from hepatitis to cirrhosis, and eventually, to HCC are unclear. This study aimed to clarify the metabolic changes that underly the progression of HCC and identify potential prognostic and therapeutic biomarkers.</div></div><div><h3>Methods</h3><div>This prospective study collected serum samples from patients with chronic hepatitis, cirrhosis, or HCC, hospitalized at the Fifth Medical Center of the PLA General Hospital, from December 2022 to December 2023. The samples were analyzed using non-targeted, ultra-high-performance liquid chromatography and mass spectrometry. Partial least squares-discriminant analysis modeling and <em>t</em>-tests were used to identify key differentially expressed metabolites associated with the progression from hepatitis to cirrhosis to HCC. Pathway enrichment analysis was conducted to determine the key metabolic pathways involved, while machine learning models were applied to identify the metabolite signatures.</div></div><div><h3>Results</h3><div>We identified 153 differentially expressed metabolites in the progression from hepatitis to cirrhosis to HCC, many of which were involved in ammonia cycling or the metabolism of methylhistidine, alanine, arginine, proline, or betaine. We also identified L-histidine and adenosine as the metabolites that demonstrated significant sensitivity and specificity for distinguishing among the hepatitis, cirrhosis, and HCC stages.</div></div><div><h3>Conclusions</h3><div>Our study comprehensively characterized the metabolic profiles of the different stages of the hepatitis-cirrhosis-HCC transition. We showed that serum metabolite detection is a viable diagnostic tool for identifying and monitoring high-risk individuals, which could potentially be used to halt the development of HCC.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100142"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging role of natural bioactive compounds in navigating the future of liver disease","authors":"Neha Chaudhary ,&nbsp;Muhammad Arif ,&nbsp;Sheeba Shafi ,&nbsp;Shom Prakash Kushwaha ,&nbsp;Pushpendra Soni","doi":"10.1016/j.iliver.2024.100140","DOIUrl":"10.1016/j.iliver.2024.100140","url":null,"abstract":"<div><div>Liver diseases, including liver inflammation, fatty liver disease, cirrhosis, and hepatocellular carcinoma, represent significant global health challenges. Traditional treatments often emphasize symptom management, leading to increased interest in natural bioactive compounds for their potential therapeutic benefits. This review examines the role of natural bioactive compounds in managing hepatic disorders, with a particular focus on their mechanisms of action and supporting clinical evidence. Compounds such as curcumin, silymarin, resveratrol, triterpenoids, apigenin, and delphinidin derivatives have demonstrated promising hepatoprotective effects in preclinical studies, largely due to their anti-inflammatory, antioxidant, and anti-fibrotic properties. Nevertheless, further research is necessary to determine optimal dosing, safety profiles, and long-term effects. Understanding the mechanisms of action and therapeutic potential of these bioactive compounds may provide critical insights into their role in the treatment of hepatic diseases.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100140"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WGCNA combined with machine learning to explore potential biomarkers and treatment strategies for acute liver failure, with experimental validation","authors":"Xinyan Wu ,&nbsp;Xiaomei Zheng ,&nbsp;Gang Ye","doi":"10.1016/j.iliver.2024.100133","DOIUrl":"10.1016/j.iliver.2024.100133","url":null,"abstract":"<div><h3>Background and aims</h3><div>To identify biomarkers to predict acute liver failure and investigate the mechanisms and immune-related pathways linked to its onset and progression.</div></div><div><h3><em>Methods</em></h3><div>We analyzed gene expression differences between patients with acute liver failure (ALF) and controls in the GSE14668 dataset. Clinically relevant modules and key ALF-associated genes were identified using weighted gene co-expression network analysis (WGCNA) in conjunction with differential gene expression (DEG) analysis. Enrichment analysis was carried out and protein–protein interaction networks were constructed to understand the functions and pathways. Six potential diagnostic biomarkers were identified using machine learning algorithms. Diagnostic performance was assessed via column charts and area under the curve calculations. Single-sample gene set enrichment analysis evaluated the relationship between known marker gene sets and potential biomarker expression. We also examined diagnostic biomarker mRNA levels in ALF models <em>in vivo</em> and <em>in vitro</em>. We estimated the relative infiltration levels of 22 immune cell subpopulations in ALF samples, and explored the link between diagnostic biomarkers and infiltrating immune cells.</div></div><div><h3><em>Result</em></h3><div>We found 352 DEGs associated with ALF. WGCNA analysis and intersecting DEGs identified 191 significant ALF-related genes. Machine learning identified <em>HORMAD2</em>, <em>WNT10A</em>, <em>ATP6V1E2</em>, <em>CMBL</em>, <em>ARRDC4</em>, and <em>LPIN2</em> as potential diagnostic biomarkers. Cell experiments and quantitative real-time polymerase chain reaction supported the therapeutic potential of eriodictyol for ALF. Immune infiltration analysis suggested that plasma cells, CD4 memory resting and activated T cells, macrophages, and neutrophils might play roles in the progression of ALF.</div></div><div><h3><em>Conclusion</em></h3><div>We identified <em>HORMAD2</em>, <em>WNT10A</em>, <em>ATP6V1E2</em>, <em>CMBL</em>, <em>ARRDC4</em>, and <em>LPIN2</em>, as diagnostic biomarkers for ALF and demonstrated the effectiveness of eriodictyol for treating ALF. Immune cell infiltration may play a significant role in the pathogenesis and progression of ALF.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100133"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural products","authors":"Pooja Yadav ,&nbsp;Khushi Quadri ,&nbsp;Renu Kadian ,&nbsp;Aafrin Waziri ,&nbsp;Pankaj Agrawal ,&nbsp;Md Sabir Alam","doi":"10.1016/j.iliver.2024.100131","DOIUrl":"10.1016/j.iliver.2024.100131","url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread and potentially severe liver condition characterized by abnormal fat accumulation in the liver unrelated to alcohol consumption. According to the World Health Organization, MASLD is the most prevalent liver disease globally, it affects approximately 25% of the world’s population, nearly two billion individuals. This staggering prevalence underscores the urgent need for effective and safe therapeutic approaches to address this escalating global health concern. Natural products have emerged as promising candidates for preventing and treating MASLD in recent years because of their diverse bioactive compounds and minimal side effects. Well-known natural products such as curcumin, resveratrol, green tea polyphenols, and silymarin exhibit notable hepatoprotective effects by influencing lipid metabolism, mitigating oxidative stress, and reducing inflammation. Ongoing research highlights the potential of phytochemicals from traditional medicinal plants, such as <em>Phyllanthus</em> and <em>Salvia</em>, in ameliorating liver steatosis and fibrosis. These natural products demonstrate the capacity to impede fibrogenesis by interfering with hepatic stellate cell activation, which is pivotal in liver fibrosis development. Recent studies underscore the significance of natural products in modulating the gut–liver axis, where they restore balance to the gut microbiota and enhance intestinal barrier function, which slows the progression of MASLD. Moreover, advancements in nanotechnology facilitate the targeted delivery of natural product-derived compounds, which enhances their bioavailability and therapeutic efficacy. Harnessing the potency of natural products offers a promising avenue for developing novel, safer therapies for MASLD and addressing a critical global health concern with far-reaching implications for public well-being.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100131"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full robotic whole graft liver transplantation: Is a new era coming?","authors":"Yipeng Pan ,&nbsp;Jimin Liu ,&nbsp;Qi Ling","doi":"10.1016/j.iliver.2024.100128","DOIUrl":"10.1016/j.iliver.2024.100128","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100128"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speaking the same language in predicting Small-for-Size Syndrome in living donor liver transplantation","authors":"Alfred Wei-Chieh Kow","doi":"10.1016/j.iliver.2024.100129","DOIUrl":"10.1016/j.iliver.2024.100129","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100129"},"PeriodicalIF":0.0,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the role of IER3+ macrophages in the prognosis of liver fibrosis by bulk and single-cell transcriptional analyses","authors":"Ling Chu ,&nbsp;Junbo Zhang ,&nbsp;Ruoyu Meng ,&nbsp;Quan Zhuang","doi":"10.1016/j.iliver.2024.100132","DOIUrl":"10.1016/j.iliver.2024.100132","url":null,"abstract":"<div><h3>Background and aims</h3><div>Liver fibrosis (LF) is the common pathological process of almost all liver diseases, but the pathogenesis is extremely complicated and has not been fully clarified. Therefore, we want to explore LF's complex pathogenesis and identify key genetic markers that can predict LF prognosis.</div></div><div><h3>Methods</h3><div>From Gene Expression Omnibus (GEO, <span><span>https://www.ncbi.nlm.nih.gov/geo/</span><svg><path></path></svg></span>), we contained datasets GSE84044 and GSE130970. And involved GSE15654 whose survival data were for the validation of our model’s prognostic value. Then, Bulk RNA sequencing was used to establish a LF-related prognostic model and to determine key genes.The key genes were later analyzed using single-cell RNA sequencing (scRNA-seq) and the role of macrophages in LF was investigated.</div></div><div><h3>Results</h3><div>We established a comprehensive LF-related prognostic model (FMSig, i.e., fibrosis macrophage-related prognostic signature) containing four genes (IER3, AKR1B10, ADCY1, and PGM1). FMSig can distinguish between survival outcomes in dataset GSE15654. IER3 showed a higher hazard ratio than the other three FMSig genes. Moreover, further scRNA-seq analysis showed that IER3 is highly expressed in myeloid cells while the other three genes were rarely expressed in six immune cell types and other cell clusters. After reclustering the myeloid cells into seven clusters, we found that IER3 was highly expressed in myeloid cell cluster 3, shown to be related to anti-inflammation and lipid metabolism functions. Based on pseudotime analysis, we suggest that myeloid cell type 3 is transformed from myeloid cell type 0 in the liver cirrhosis microenvironment. On immunohistochemical staining, LF showed significantly higher IER3 expression than healthy controls.</div></div><div><h3>Conclusion</h3><div>This study established a predictive model, FMSig, to evaluate LF prognosis, and showed that IER3 and macrophages are related to LF.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”","authors":"Binghua Li ,&nbsp;Qiang Wang ,&nbsp;Weiwei Hu ,&nbsp;Huan Li ,&nbsp;Peng Yan ,&nbsp;Yajuan Cao ,&nbsp;Decai Yu","doi":"10.1016/j.iliver.2024.100130","DOIUrl":"10.1016/j.iliver.2024.100130","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100130"},"PeriodicalIF":0.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142719874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Danning tablets for the treatment of multiple gallbladder polyps: Study protocol of multicentre, randomised, open-labelled, controlled trial","authors":"Tian Yang ,&nbsp;Ming-Da Wang ,&nbsp;Gui-Lin Xie ,&nbsp;Xiong-Hua Wang ,&nbsp;Liu Zheng ,&nbsp;Li-Min Wang ,&nbsp;Guang-Fa Xiao ,&nbsp;Yong-Qing Yang ,&nbsp;Chao Li ,&nbsp;Alfred Wei Chieh Kow ,&nbsp;Feng Shen","doi":"10.1016/j.iliver.2024.100127","DOIUrl":"10.1016/j.iliver.2024.100127","url":null,"abstract":"<div><h3>Introduction</h3><div>Gallbladder polyps (GPs) are protrusions of the gallbladder wall into the lumen, and are commonly detected during ultrasound examinations. Traditional management of multiple GPs (MGPs) has been conservative, including lifestyle interventions, regular monitoring, and surgical intervention in certain cases, but this approach poses risks of polyps enlargement and increase of number, as well as patients’ psychological burdens. Danning Tablets, a traditional Chinese medicine, have emerged as a potential non-surgical treatment for GPs, showing promise in reducing polyp size and alleviating symptoms, backed by their anti-inflammatory and antitumor properties demonstrated in preclinical studies. This suggests the need for further research into Danning Tablets as an alternative treatment for MGPs.</div></div><div><h3>Methods and analysis</h3><div>The study is designed as a prospective, randomized, controlled, open-label trial. The study will be conducted across multiple centres specializing in gastroenterology and hepatology. Participants will be recruited from these centres, ensuring a diverse patient demographic. Adult patients diagnosed with MGPs, based on ultrasound findings, will be included. Exclusion criteria include patients with a history of gallbladder cancer, previous gallbladder surgery, or serious comorbid conditions. The control group will receive standard care, including dietary and lifestyle advice, while the intervention group will receive Danning Tablets and standard care. The dosage and administration of Danning Tablets will follow established clinical guidelines. The primary outcome will be the change in size of the largest gallbladder polyps on week 24 ± 1, measured by ultrasound. The secondary outcomes will include symptom improvement and recording of any adverse events. The study will span over a period of 6 months, with periodic assessments at baseline, 4, 8, 12, and 24 weeks.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100127"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}